Volume, clinician adoption, ASP, and profitability improved, but quarterly collections remain difficult to forecast.
| Quarter | Q1 FY26 |
|---|---|
| Call date | 2026-05-13 |
| Length | 47 minutes |
| EPS | $-0.17 |
| EPS consensus | $-0.24 |
| Revenue | $17.3M |
What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.
Other quarters: Q2 FY26 · Q2 FY25
All XGN earnings · Back to XGN overview
Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.